Chemomab adjourns 2026 shareholder meeting for quorum

Chemomab Therapeutics Ltd. has adjourned its Annual General Meeting of Shareholders due to a lack of quorum.

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. has adjourned its Annual General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for April 28, 2026 in Ramat Gan, Israel, has been postponed to May 5, 2026 at the same time and location.

The agenda and proposed resolutions remain as set out in the proxy statement furnished on March 20, 2026, which continues to govern the matters to be voted on. This report is also incorporated by reference into Chemomab’s existing Form F-3 and Form S-8 registration statements.

Key Figures

Original AGM date: April 28, 2026 Adjourned AGM date: May 5, 2026 Proxy statement filing date: March 20, 2026

3 metrics

Original AGM date April 28, 2026 Initial Annual General Meeting date in Israel

Adjourned AGM date May 5, 2026 New date for Annual General Meeting after adjournment

Proxy statement filing date March 20, 2026 Date Chemomab furnished Form 6-K with proxy statement

Key Terms

Annual General Meeting of Shareholders, lack of quorum, proxy statement, Registration Statements on Form F-3, +1 more

5 terms

Annual General Meeting of Shareholders financial

"its Annual General Meeting of Shareholders (the “Meeting”) has been adjourned"

lack of quorum regulatory

"to Tuesday, May 5, 2026 ... due to a lack of quorum"

proxy statement regulatory

"including a proxy statement, which includes the full version of the proposed resolutions"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

Registration Statements on Form F-3 regulatory

"incorporated by reference into the Company’s Registration Statements on Form F-3"

Form S-8 regulatory

"Registration Statements on Form F-3 ... and Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Chemomab Therapeutics (CMMB) adjourn its 2026 Annual General Meeting?

Chemomab adjourned its 2026 Annual General Meeting because there was a lack of quorum at the originally scheduled session. Without sufficient shareholder participation, the company could not legally conduct votes on the proposed resolutions outlined in its previously distributed proxy statement.

When will Chemomab Therapeutics (CMMB) hold the adjourned Annual General Meeting?

The adjourned Annual General Meeting is scheduled for May 5, 2026, at 4:30 p.m. Israel time. It will take place at Meitar Law Offices in Ramat Gan, Israel, at the same venue and time as initially planned for the original April 28, 2026 meeting.

Do the agenda and resolutions change for Chemomab’s May 5, 2026 shareholder meeting?

The agenda and proposed resolutions remain those included in the proxy statement furnished on March 20, 2026. Shareholders should refer to that proxy statement for full details on the items to be considered and voted on at the adjourned Annual General Meeting.

Where can Chemomab (CMMB) shareholders find more details about the 2026 meeting items?

Shareholders can find detailed information in the proxy statement that accompanied Chemomab’s Form 6-K furnished on March 20, 2026. That document includes the full text of the proposed resolutions and explanatory materials regarding each agenda item for the Annual General Meeting.

How does this Form 6-K affect Chemomab’s Form F-3 and Form S-8 registrations?

This Form 6-K is incorporated by reference into Chemomab’s Form F-3 and Form S-8 registration statements. Incorporation by reference means the information about the adjourned meeting becomes part of those registration documents for U.S. securities law disclosure purposes.

Where is Chemomab’s adjourned Annual General Meeting being held?

The adjourned Annual General Meeting will be held at Meitar Law Offices, 16 Abba Hillel Road, 10th floor, Ramat Gan, Israel. The company confirmed that the location and time remain unchanged from the original April 28, 2026 meeting notice to shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 04:06 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number 001-38807

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

10 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

EXPLANATORY NOTE

Chemomab Therapeutics Ltd. (the “Company”) hereby announces that its Annual General Meeting of Shareholders (the “Meeting”) has been adjourned from Tuesday, April 28, 2026, at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel, to Tuesday, May 5, 2026, at the same time and place, due to a lack of quorum.

On March 20, 2026, the Company furnished to the Securities and Exchange Commission a Report of Foreign Private Issuer on Form 6-K, including a proxy statement, which includes the full version of the proposed resolutions. See the proxy statement for more information regarding the Meeting and the agenda items.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHEMOMAB THERAPEUTICS LTD.
Date: April 28, 2026	By:	/s/ Sigal Fattal
		Sigal Fattal
		Chief Financial Officer